fbpx

QQQ
+ 1.85
363.85
+ 0.51%
BTC/USD
-781.70
42233.92
-1.82%
DIA
+ 1.16
338.24
+ 0.34%
SPY
+ 1.67
432.37
+ 0.38%
TLT
-0.34
151.36
-0.22%
GLD
+ 1.04
163.90
+ 0.63%

Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation

November 25, 2019 11:40 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation

Arvinas Inc (NASDAQ:ARVN) shares have been on a tear ever since the company issued a platform update in late October.

The Analyst

Guggenheim Securities analyst Michael Schmidt initiated coverage of Arvinas with a Buy rating and $50 price target. 

The Thesis

Arvinas, a small-cap, early clinical-stage biotech, is focused on developing PROTAC-based targeted protein degradation therapies, an emerging therapeutic modality of great potential, Schmidt said in a Monday note. (See his track record here.)

TPD therapies, according to the analyst, have potential advantages over traditional inhibitors with respect to "dosing, potential side effects, drug resistance mechanisms and ability to address undruggable targets," the analyst said. 

See Also: Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio

The company has two early stage assets in the pipeline: ARV-110, an androgen receptor degrader for treating metastatic castration-resistant prostate cancer, or nCRPC; and ARV-471, an estrogen receptor degraded for treating ER+/HER2- breast cancer patients.

Initial data for ARV-110 is due in the first half of 2020 and ARV-471 data is due in the second half of 2020, Schmidt said. 

"ARVN is taking a conservative, step-wise approach towards clinical development that may mitigate some near-term development risks, in our view," the analyst said. 

Guggenheim's base-case scenario assumes peak sales potential of $1.5 billion in PoS-adjusted worldwide sales of ARV-110 and ARV-471 in 2037, with $800 million attributable to the former and the rest to the latter.

Additionally, Schmidt sees PROTAC for neurology indications, additional partnerships and rest of the pipeline serving as potential sources of upside from its current valuation.

Price Action

Arvinas shares were trading 0.32% higher at $34.78 at the time of publication Monday. 

Related Link: Benzinga's Top Upgrades, Downgrades For November 25, 2019

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

UPDATE: Roth On Arvinas: Firm Highlights $2B Collaboration With Pfizer For ARV-471 Estrogen Receptor Degrader In Breast Cancer With Co. Receiving $650M Upfront, $400M Upon Approval & Up To $1B For Commercial Milestones; Selects Co. As 2H2021 Top Pick

UPDATE: Goldman On Arvinas Says Raises Odds Of Success For Co.'s ARV-471 From 25% To 45% Following New Data Disclosed Monday

Arvinas Shares Rebound From Intraday Low; Traders Circulate Word Wedbush Raised Price Target To New Street High Of $93; BZ NOTE: Target Suggests Potential Upside Of ~48% From Where Stock Currently Trading

5 ASCO Abstracts Moving Biopharma Stocks

5 ASCO Abstracts Moving Biopharma Stocks

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe. This year's meeting is is scheduled for May 29-31 and is organized as a virtual event due to the lockdowns and stay-at-home restrictions necessitated by the COVID-19 pandemic. read more